Aquestive Therapeutics, a drug manufacturer developing oral film formulations of CNS disease therapies, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering.
The Warren, NJ-based company was founded in 2004 and booked $74 million in sales for the 12 months ended March 31, 2018. It plans to list on the Nasdaq under the symbol AQST. Aquestive Therapeutics filed confidentially on April 2, 2018. BMO Capital Markets and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
